CTLA4 and hypopituitarism: While more common with cytotoxic T-lymphocyte-associated antigen 4 inhibitors, pembrolizumab-induced hypophysitis is increasingly recognized, with presentations ranging from isolated ACTH deficiency to full hypopituitarism [4-6].